Robotic-assisted PCI
DeviceRobotic-assisted PCI will be performed according to the routine hospital practices, current scientific guidelines and following Instructions for Use (IFU) provided by the manufacturer
NCT Number: NCT05853419
The main objective of the CHANGE registry is the evaluation of the real-world performance and safety profile of the R-One System in PCI.
Interested in participating?
Request Info18 year–120 year
All sexes
Observational
Het Ziekenhuisnetwerk Antwerpen vzw, Antwerp, Belgium
The R-One system is a class "IIb" CE marked medical device designed to remote deliver and manipulate coronary guidewires and stent/balloon devices during Percutaneous Coronary Intervention (PCI). The system comprises the R-One Robotic Platform used in combination with two accessories, the Mobile Radioprotection Screen and a sterile and single-use R-One Consumable Kit. The R-One is not autonomous and operates only under the operator's commands.
This study is a single-arm, open-label, multi-center registry.
The CHANGE registry, part of the ROBOCATH's post-market clinical follow-up activities, is a real world study aiming to confirm the safety and performance, including the clinical benefit, of the R-One robotic systems medical device.
500 patients with coronary artery disease and with clinical indication for PCI will be recruited in up to Up to 15 centers distributed in Europe and South Africa.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Robotic-assisted PCI will be performed according to the routine hospital practices, current scientific guidelines and following Instructions for Use (IFU) provided by the manufacturer
Time frame: From Day 0 to Day 3
Less than 30% residual stenosis (visual estimate) post PCI in the lesion(s) treated with the R-One System, without in-hospital major adverse cardiac events (MACE).
Time frame: During procedure
Absence of any unplanned manual assistance or conversion to manual PCI for procedural completion
Time frame: During procedure
Dose (DSP and Air Kerma) measured by the imaging system during the procedure.
Time frame: During procedure
Defined as the time measured from the insertion of the hemostasis sheath until the removal of the guide catheter.
Time frame: During procedure
Total volume of contrast (mL) used during the procedure.
Time frame: During procedure
Cumulative dose the operator receives as recorded from an electronic pocket dosimeter during the procedure.
Time frame: During procedure
Total fluoroscopy utilized during the procedure as recorded by an Imaging System.
Time frame: From Day 0 to Day 3
Medical device's safety event occurrence
Contact information is provided by the study sponsor or research team.
Robocath
Industry
Acronym: CHANGE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07258290
Acute Coronary Syndrome, Angina Pectoris
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06736899
Arterial Occlusive Diseases, Arteriosclerosis
Alicante, Spain
View Trial DetailsNCT01621594
Cardiovascular Diseases, Coronary Disease
Bethesda, Maryland, United States
View Trial DetailsNCT03588481
Cardiovascular Diseases, Coronary Disease
Incheon, South Korea
View Trial Details